Evaluating the effect of certain drugs on rheumatoid arthritis activity
Clinical Study Evaluating the Effect of Histamine 1 Receptor Antagonist and Leukotreine Receptor Antagonist on Patients With Rheumatoid Arithritis
This study is testing whether the medications Rupatadine and Montelukast can help reduce symptoms and improve the condition of people with rheumatoid arthritis.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 75 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Tanta) |
| Trial ID | NCT03770923 on ClinicalTrials.gov |
What this trial studies
This study evaluates the impact of specific medications, Rupatadine and Montelukast, on the activity levels of rheumatoid arthritis in patients. It is an interventional Phase 3 trial designed to assess how these drugs can influence disease symptoms and progression. The study will involve monitoring patient responses to the treatments over a defined period to determine their effectiveness in managing rheumatoid arthritis.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with rheumatoid arthritis.
Not a fit: Patients with liver or renal disease may not receive benefit from this study due to exclusion criteria.
Why it matters
Potential benefit: If successful, this study could provide new treatment options that significantly improve the management of rheumatoid arthritis symptoms.
How similar studies have performed: There is limited information on the success of similar approaches, making this study somewhat novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Rheumatoid arthritis Exclusion Criteria: * liver or renal disease
Where this trial is running
Tanta
- Sherief Abd-Elsalam — Tanta, Egypt (Recruiting)
Study contacts
- Principal investigator: Sahar k Hegazy, Prof — Head of Clinical Pharmacy Department
- Study coordinator: Sherief Abd-Elsalam, Ph D
- Email: sheriefabdelsalam@yahoo.com
- Phone: 00201147773440
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.